Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00471640
Status:
COMPLETED
Last Update Posted:
2010-09-27
First Post:
2007-05-08
Brief Title:
Dexamethasone Infusion in Community-acquired Pneumonia
Sponsor:
St Antonius Hospital
Organization:
St Antonius Hospital
Study Overview
Official Title:
Dexamethasone Infusion in Community-acquired Pneumonia
Status:
COMPLETED
Status Verified Date:
2010-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Ovidius
Brief Summary:
The purpose of this study is to determine whether dexamethasone reduces the length of hospital stay in patient with a community-acquired pneumonia
Detailed Description:
Community-acquired pneumonia CAP is common and approximately 20 percent of all episodes of pneumonia result in hospitalization It is the leading cause of community-acquired infection requiring ICU admission1 Especially elderly patients may have a severe illness with a high morbidity and mortality rate In pulmonary infections the release of cytokines and other inflammatory mediators from alveolar macrophages serves as a useful mechanism in the elimination of invading pathogens However this natural reaction can be potentially harmful when excessive release of circulating inflammatory cytokines causes damage to the patient particularly the lung
Interest in the role of corticosteroids in the pathophysiology of critical illness has existed since the early part of the 20th century On ICU early treatment with corticosteroids to attenuate systemic inflammation is widespread At the same time outside the ICU little evidence is available on the effect of treatment with corticosteroids in patients diagnosed with CAP Hypothetically early initiated administration of corticosteroids in the course of a CAP can lower systemic and pulmonary inflammation This may lead to earlier resolution of pneumonia and a reduction of complications sepsis mortality
Interest in the role of corticosteroids in the pathophysiology of critical illness has existed since the early part of the 20th century On ICU early treatment with corticosteroids to attenuate systemic inflammation is widespread At the same time outside the ICU little evidence is available on the effect of treatment with corticosteroids in patients diagnosed with CAP Hypothetically early initiated administration of corticosteroids in the course of a CAP can lower systemic and pulmonary inflammation This may lead to earlier resolution of pneumonia and a reduction of complications sepsis mortality
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None